Background: Non small cell lung cancer was the leading cause of cancer death worldwide. five-year survival of pathologic stage IIIa still remain poor and the management remain controversial. Many new medicines and surgical techniques were utilized as treatment for pathologic stage IIIIa patient. The aim of study was tried to analyzed the survival impact of these treatment modalities and the stage migration effect during new TNM staging classification system. Method: From Jan 2005 to Jun 2014, there were 166 pathologic stage IIIa patients were enrolled into study. All patients were follow up till 2016/7. Patients were divided into two groups since year 2010 because of difference of surgical technique switch. Medical records were reviewed retrospectively and survival status were analyzed. Result: From January 2005 to May 2014, 166 patients who had received tumor resection and were confirmed as pathologic stage IIIa by 7th AJCC stage classification system were included for further analysis. The 5-year disease free and overall survival rates were 24.9% and 38.2%, respectively. Patients who received neoadjuvant therapy showed inferior disease free survival compared with those without neoadjuvant therapy. ( p< 0.0001). Patients who presented as adenocarcinoma and received tumor resection showed better overall survival than non-adenocarcinoma patients. (p¼0.0011) Because the operation method was shifted to video-assisted thoracoscopic surgery in the year 2010, we analyzed survival status separately before and after 2010. In addition, we found that patients who received tumor resection and were conformed as pathologic stage IIIa adenocarcinoma has had better overall survival than other subgroups. (p ¼0.0005) 28 patients who were identified stage migration had worse disease-free and overall survival. Conclusion: Disease free survival of pathologic stage IIIa patients remain unchanged but overall survival had much improvement. Patients who presented with adenocarcinoma who received tumor resection during 2010 to 2014 has better survival. This may be related to medical improvement but further investigation was warranted. Stage migration and worse disease and overall survival for those presented as 3b in new stage classification were identified. Different treatment strategy was needed for these patients who were identified stage migration.
P1.16-10 Marginal Features Analyses of Lung Adenocarcinoma for Survival Prediction G. Lee, 1 H.Y. Lee, 2 H. Park 3 1 Radiology, Pusan National University Hospital, Busan/KR, 2 Samsung Medical Center, Seoul/KR, 3 Sungkyunkwan University, Suwon/KR Background: Tumor microenvironment is a complex mixture of assorted cells and extra-cellular components which make up an amazingly dynamic area that includes signaling interactions between cancer cells and their surrounding tissue. Tumor microenvironment makes up the peripheral portion of the tumor and major changes in this area has been reported to be associated with a poor prognosis. However, very few studies have investigated the tumor marginal features quantitatively extracted from CT images using a radiomics approach. We aimed to clarify the relationship between tumor marginal features and the micropapillary pattern and correlated with survival. Method: We enrolled 334 patients who underwent complete resection for lung adenocarcinoma. Quantitative histologic subtyping was performed for the whole tumor. Using a radiomics approach, quantitative CT analysis was performed and 82 marginal features were extracted. Clinical variables and marginal features were correlated with survival. Using selected clinical variables and marginal features a prognostic model was calculated with subsequent internal and external validation. Result: Among various subtypes, solid predominant adenocarcinomas had the lowest proportion (6.9%) of combined micropapillary pattern. At univariate analysis, patient age, tumor size, and multiple marginal features (convexity, surface area, compactness, maximum 3D diameter, sphericity, surface-to-volume ratio, mean pixel value, median pixel value, entropy, uniformity, skewness, kurtosis, roundness factor, solidity, and lacunarity) were predictive of survival. At multivariate cox proportional analysis, convexity (P¼0.017), kurtosis (P<0.001), and patient age (P¼0.006) were identified as being predictive of survival. Ten-fold cross-validation tests demonstrated that our prediction model significantly classified patients according to survival (P<0.001). Although lower than internal validation, the prediction model also worked at external validation. Conclusion: Marginal radiomics features of convexity and kurtosis reflect the tumor microenvironment and were predictive of patient survival in lung adenocarcinomas. Keywords: Tumor margin, Adenocarcinoma, Radiomics
P1.16-11 Monitoring of Early Stage Lung Cancer Using Liquid Biopsies
A. Dobrovic Olivia Newton-John Cancer Research Institute, Hedielberg, VIC/AU Background: This study aims to validate the use of chromosome rearrangements as tumour-specific biomarkers for the detection of circulating tumour DNA (ctDNA) to enable monitoring of cancer using digital PCR. We consider that rearrangements are the best source of robust disease markers that can be used for every lung cancer patient without a clear truncal mutation. The current high cost of the whole genome sequencing required for identification of chromosome rearrangements is offset by the low cost, high sensitivity and specificity of the subsequent assays. Method: s for ctDNA detection using chromosome rearrangements that leverage advances in next generation sequencing (NGS), bioinformatics and droplet digital PCR (ddPCR) have now been developed by our laboratory. Result: We are using whole genome sequencing and bioinformatic analysis of lung tumour samples. The genomic sequence was aligned to the human reference genome (hg19). Rearrangements were identified using the GRIDSS algoriths. Large numbers of potential genomic rearrangements that could be used as a biomarker to detect ctDNA were identified in each tumour. These were used to design primers which were used to monitor the success of surgical resection and to detect early relapse. Conclusion: Patients with early-stage primary tumours are the group in which appropriately timed therapeutic intervention is most likely to make a clinical difference. Our study assesses ctDNA in a large cohort of lung cancer patients
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